Invitae
Invitae to Acquire Consumer Health Tech Firm Ciitizen for $325M
The company focused on aggregating genomic content in one service believes Ciitizen will enhance its goal by enabling patients to aggregate and share their data to improve healthcare.
Jury Awards ArcherDx, MGH $4.7M in Qiagen Patent Infringement Lawsuit
A federal jury ruled that various Qiagen sample prep products infringe a pair of US patents underlying ArcherDx's anchored multiplex PCR technology.
Invitae Writes off $262.5M Liability Upon Failure to Meet Regulatory Milestone
The company still expects the Stratafide cancer test to achieve FDA approval or clearance, but after March 31, 2022.
Invitae More Than Doubles Q2 Revenues
The company reported $116.3 million in revenues compared to $46.2 million a year ago, which exceeded Wall Street expectations.
GenomeWeb Index Gains Slightly in July as Fluidigm, PerkinElmer, Bio-Rad Post Strong Increases
The GenomeWeb Index outperformed the Dow Jones, Nasdaq, and Nasdaq Biotechnology Index last month.
May 4, 2021
Invitae Q1 Revenues Increase 61 Percent
Feb 17, 2021
Invitae Q4 2020 Revenues Increase 51 Percent
Feb 1, 2021
Oppenheimer Downgrades Invitae to Perform Rating
Jan 22, 2021
Invitae Prices $400M Common Stock Offering
Jan 20, 2021
Invitae to Raise $400M in Proposed Public Offering
Jan 11, 2021
Invitae 2020 Preliminary Revenues Rise 28 Percent
Dec 28, 2020